Detalhe da pesquisa
1.
Predicting disease progression in high-grade glioma with neuropsychological parameters: the value of personalized longitudinal assessment.
J Neurooncol
; 144(3): 511-518, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31342318
2.
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Lancet Oncol
; 15(9): 943-53, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25035291
3.
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
Cancer Res
; 76(3): 525-34, 2016 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26762204
4.
The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
Eur J Cancer
; 51(10): 1321-30, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25899986
5.
Acute neurological disorders following intraperitoneal administration of cisplatin.
Int J Gynaecol Obstet
; 120(3): 291, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23245673